NCT02013791 - Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 29, 2014

Primary Completion Date

April 12, 2017

Study Completion Date

April 12, 2017

Conditions

Dry Eye Syndromes

Interventions

DRUG

Vehicle

Vehicle of cyclosporine administered as per protocol

OTHER

Sham

Sham administered to non-study eye as per protocol on Day 1

DRUG

Cyclosporine New Ophthalmic Formulation

Cyclosporine New Ophthalmic Formulation administered as per protocol

Trial Locations (8)

Johns Hopkins University - Wilmer Eye Institute, Baltimore

Eye Centers of Racine and Kenosha, Kenosha

Vision Institute, Colorado Springs

Wolstan & Goldberg Eye Associates, Torrance

Sall Research Medical Center, Artesia

Lugene Eye Institute, Glendale

Lakeside Vision Center, Irvine

Steve Yoelin MD Medical Asscociates, Newport Beach